{"page":{"totalFilteredElements":12},"studies":[{"active":true,"description":"Long-Term Follow-up of\nPatients Treated with Miltenyi Cell and Gene Therapies [Longsafe\n  MB-CARTSAFE\n  (M-2022-393)<div>]</div>","eudractNumber":"2022-501648-14-00","id":8725,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped2","name":"Lymphome"}],"mutations":[],"nctNumber":"NCT06508775","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2024-05-05T14:13:36+02:00","shortTitle":"Longsafe","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2</div><div>Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma</div><div><br /></div>","eudractNumber":"2024-517140-65","id":11953,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"},{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT06953960","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2026-04-30T15:02:51+02:00","shortTitle":"Multiple Myeloma: Evaluate the Safety and Efficacy of ABBV-453 in Monotherapy or in Combination with Antimyeloma Regimens","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]}]}